Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03097029 · ClinicalTrials.gov registry record · Phase 2
Use of Pancreatic Enzymes in Short Bowel Syndrome
A Phase 2 study, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT03097029 is a Phase 2 study that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 16 participants.
The verdict
NCT03097029, a Phase 2 study, has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
Patients with short bowel syndrome have a high mortality rate that is mainly attributed to complications from central lines and long-term intravenous (IV) nutrition. There are few medical therapies to date that improve gut absorption in patients with short bowel syndrome. The primary objective of this study is to evaluate if absorption from the GI tract improves in subjects with short bowel syndrome following therapy with pancreatic enzymes.
Interventions
- DRUG Pancreatic Enzyme
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2017-03-24 |
| Est. Completion | 2019-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03097029
The ClinicalTrials.gov registry entry for NCT03097029 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pancreatic Enzyme is the first listed.
NCT03097029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03097029 about?
NCT03097029 is a clinical study titled "Use of Pancreatic Enzymes in Short Bowel Syndrome". Patients with short bowel syndrome have a high mortality rate that is mainly attributed to complications from central lines and long-term intravenous (IV) nutrition. There are few medical therapies to date that improve gut absorption in patients with short bowel syndrome. The primary objective of th...
What is the current status of trial NCT03097029?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2017-03-24. Estimated completion is 2019-02-01.
What interventions are being tested in trial NCT03097029?
The interventions under investigation include: Pancreatic Enzyme (DRUG).
Who is sponsoring clinical trial NCT03097029?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.